menu search

NVRO / Nevro to Report Fourth Quarter and Full-Year 2022 Financial Results

Nevro to Report Fourth Quarter and Full-Year 2022 Financial Results
Company to Host Conference Call on Thursday, February 16, 2023 at 1:30 pm PT / 4:30 pm ET REDWOOD CITY, Calif. , Jan. 19, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the company will report its financial results for the fourth quarter and full year ended December 31, 2022 after the market closes on February 16, 2023. Read More
Posted: Jan 19 2023, 07:00
Author Name: PRNewsWire
Views: 111673

NVRO News  

Nevro: Economic Realities Too Deep To Ignore, Downgrade To Hold

By Seeking Alpha
September 1, 2023

Nevro: Economic Realities Too Deep To Ignore, Downgrade To Hold

Nevro Corp. shares have significantly underperformed, selling 57% lower than in 2021. The company's top-line momentum continues, but it faces economic more_horizontal

Nevro's (NVRO) Latest Launch to Customize Chronic Pain Treatment

By Zacks Investment Research
August 15, 2023

Nevro's (NVRO) Latest Launch to Customize Chronic Pain Treatment

Nevro's (NVRO) HFX Connect system is expected to treat individual patients per their requirements with 35 pre-programmed customizable plans. more_horizontal

Why Shares of Nevro Are Down Wednesday

By The Motley Fool
August 2, 2023

Why Shares of Nevro Are Down Wednesday

Nevro said it expects third-quarter revenue to fall between 4% to 6% year over year. The company is reorganizing its sales force. more_horizontal

Nevro Corp. (NVRO) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 1, 2023

Nevro Corp. (NVRO) Q2 2023 Earnings Call Transcript

Nevro Corp. (NYSE:NVRO ) Q2 2023 Earnings Conference Call August 1, 2023 4:30 PM ET Company Participants Greg Chodaczek - Gilmartin Group LLC Kevin Th more_horizontal

Nevro (NVRO) Reports Q2 Loss, Misses Revenue Estimates

By Zacks Investment Research
August 1, 2023

Nevro (NVRO) Reports Q2 Loss, Misses Revenue Estimates

Nevro (NVRO) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $0.71 more_horizontal

3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio

By Zacks Investment Research
June 19, 2023

3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio

Investors continue to be optimistic about Nevro (NVRO) due to its R&D edge. more_horizontal

Nevro: Potentially Better Than Traditional SCS Treatment For Pain And Undervalued

By Seeking Alpha
May 9, 2023

Nevro: Potentially Better Than Traditional SCS Treatment For Pain And Undervalued

Nevro is a company dedicated to the design and manufacture of medical devices. I believe that further news about the efficacy of the product, sufficie more_horizontal

Nevro (NVRO) Q1 Earnings and Revenues Surpass Estimates

By Zacks Investment Research
April 27, 2023

Nevro (NVRO) Q1 Earnings and Revenues Surpass Estimates

Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q1, partly owing to robust domestic performance. more_horizontal


Search within

Pages Search Results: